Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes

Table 5

Adverse events.

	Dapagliflozin	Empagliflozin
Total adverse events	134	95
Serious adverse events	3	1
Patient had more than one adverse event	9	8
AEs leading to discontinuation	116 (86.6%)	85 (89.5%)
Genital mycotic infections	19 (14.2%)	23 (24.2%)
Urinary tract infections	26 (19.4%)	17 (17.9%)
Hypotension	1 (0.8%)	2 (2.1%)
Dizziness	10 (7.5%)	9 (9.5%)
Skin itching/eruption	13 (9.7%)	8 (8.4%)
Hypoglycemia	0	0
Diabetic ketoacidosis	3 (2.2%)	0
Renal impairment	1 (0.8%)	3 (3.2%)
Gastrointestinal symptoms†	16 (11.9%)	8 (8.4%)
Lower urinary tract symptoms††	18 (13.4%)	22 (23.1%)
Others‡	33 (24.6%)	11 (11.6%)

†Gastrointestinal symptoms: abdominal fullness, abdominal pain, constipation, diarrhea, gastroesophageal reflux disease, nausea, and vomiting. ††Lower urinary tract symptoms: dysuria, frequent urination, nocturia, polyuria, and urination discomfort. ‡Others: acute pyelonephritis, discomfort, edema, foam urine, headache, hematuria, hunger, lumbar pain, muscle pain, palpitation, chest tightness, weakness, and weight loss.